Skip to main content
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRDA ISIN · US29384C1080 US Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2022-11-07 Earnings Release
Country US United States of America
Listing US TRDA

About Entrada Therapeutics, Inc.

https://www.entradatx.com/

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of medicines to treat devastating diseases. The company's proprietary Endosomal Escape Vehicle (EEV) platform is designed to enable the intracellular delivery of a wide range of therapeutics, allowing access to targets that have historically been considered undruggable. Entrada's development pipeline is concentrated on rare conditions, with programs targeting neuromuscular diseases, including Duchenne muscular dystrophy, as well as ocular diseases. The company's mission is to transform the lives of patients by establishing EEV-based therapeutics as a new treatment modality.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates. The text specifically mentions "Item 2.02 Results of Operations and Financial Condition" and states that the company announced its financial results for the quarter ended September 30, 2022, along with other corporate updates. It also references a press release as an exhibit. The document is 3707 characters long, which is relatively short and primarily serves as an announcement of the earnings release rather than containing detailed financial statements or analysis itself. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2022-11-07 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a formal communication related to a capital raising process but does not contain financial statements or detailed financial data. The document is short (1576 characters) and is a regulatory communication rather than a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement related to securities registration and compliance.
2022-11-04 English
Regulatory Filings 2022
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify this document into any specific filing category. According to the rules, when a document does not neatly fit into any category and lacks identifiable content, it should be classified as a Regulatory Filing (RNS) as a fallback category.
2022-11-03 English
FORM 4
Director's Dealing
2022-11-02 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Entrada Therapeutics, Inc. It is a registration statement under the Securities Act of 1933 used for registering securities offerings, typically for shelf registrations allowing the company to offer securities up to a certain amount over time. The text includes a detailed table of contents for the prospectus, risk factors, forward-looking statements, and descriptions of securities to be offered. It is not a financial report, earnings release, management discussion, or any other report type but rather a capital markets filing related to securities issuance. According to the filing definitions, updates on company fundraising or financing activities or capital structure changes fall under Capital/Financing Update (CAP). Since this is a registration statement for securities offerings, it fits best under Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, not just an announcement or notice, so it is not RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2022-11-01 English
FORM 4
Director's Dealing
2022-10-28 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.